Journal
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
Volume 37, Issue 5, Pages 644-649Publisher
WILEY-BLACKWELL
DOI: 10.1002/hed.23647
Keywords
salivary gland cancer; adenoid cystic carcinoma; non-adenoid cystic carcinoma; gefitinib; response to therapy
Categories
Funding
- Astra-Zeneca [IRUSIRE0198]
Ask authors/readers for more resources
BackgroundThe purpose of this study was to determine the antitumor activity of the epidermal growth factor receptor (EGFR) inhibitor gefitinib in patients with recurrent/metastatic salivary gland cancer. MethodsWe conducted a phase II study in adenoid cystic carcinoma (ACC) and non-ACC. Gefitinib was administered 250 mg orally daily. The primary endpoint was tumor response. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and disease control rates. EGFR and human epidermal growth factor receptor 2 (HER2) expression were evaluated and correlated with outcomes. ResultsThirty-seven patients were enrolled in this study, and 36 were evaluable (18 with ACC and 18 with non-ACC). No responses were observed. Median PFS was 4.3 months and 2.1 months, and median OS was 25.9 months and 16 months for patients with ACC and non-ACC, respectively. The disease control rate at 8 weeks was higher in patients with ACC. No unexpected toxicities occurred. EGFR and HER2 overexpression did not correlate with outcomes. ConclusionWe did not observe significant clinical activity of gefitinib in advanced salivary gland cancer. NCT00509002. (c) 2015 Wiley Periodicals, Inc. Head Neck37: 644-649, 2015
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available